PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v1i2.21ArticleApplication of Traditional Chinese Medicine Combined with TACE in Patients with Primary Hepatocellular Carcinoma and Its Effect on Liver Functionhttps://artdesignp.com/journal/PAR/1/2/10.26689/par.v1i2.21DingHaibin2020122020-12-31Objective: To analyze the effects of Chinese herbal medicine combined with transcatheter arterial chemoembolization (TACE) on liver function in patients with primary hepatocellularCarcinoma (HCC). Methods: 122 patients with primary hepatocellular carcinoma admitted in our hospital from March 2014 to October 2016 were divided into experimental group and control group according to the digital table. The number of each group was the same. The patients in the control group were treated by transcatheter arterial chemoembolization. The experimental group was treated with traditional Chinese medicine on the basis of the control group. SPSS20.0 statistical software for statistical analysis of two groups of patients with short-term effect, follow-up of one year primary liver cancer recurrence rate, before and after treatment WBC count, liver function (alanine aminotransferase), alpha-fetoprotein and Karnofsky index parameters. Results: ①The total effective rate of the experimental group was significantly higher than that of the control group (P <0.05); ②The relapse rate of theexperimental group was significantly lower than that of the control group (P <0.05); ③ Before the treatment, the patients in the two groups had significantly higher recurrence rate than those in the control group (P <0.05). After treatment, the white blood cell count, liver function and alpha-fetoprotein levels in the experimental group were significantly better than those in thecontrol group (P <0.05), but no significant difference was found between the two groups (P<0.05). ④ The Karnofsky score of the experimental group was significantly higher than that of the control group (P<0.05). Conclusion: Chinese medicine combined with transcatheter arterial chemoembolization in patients with primary liver cancer in the application value is relatively high.